Go Deep
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,984 | 42.3 | 5.92 | 0.35 | 1,200.80 |
Senores Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,802,100,000.0 | 1,751,900,000.0 | 1,648,500,000.0 | 1,533,600,000.0 |
| Net Profit | 307,200,000.0 | 316,100,000.0 | 316,600,000.0 | 323,800,000.0 |
| EPS | 6.6 | 8.0 | 7.3 | 6.5 |
Senores Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 6,141,800,000.0 | 3,806,000,000.0 | 2,107,800,000.0 | 353,260,000.0 | — |
| Net Profit | 1,153,800,000.0 | 585,600,000.0 | 314,500,000.0 | 84,330,000.0 | — |
| EPS | 26.4 | 16.1 | 6.8 | 1.8 | — |
Senores Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 16,038,100,000.0 | 12,268,600,000.0 | 6,218,800,000.0 | 1,310,530,000.0 | — |
| Total Liabilities | 6,392,700,000.0 | 4,146,100,000.0 | 3,901,700,000.0 | 855,540,000.0 | — |
| Total Equity | 9,336,000,000.0 | 7,861,900,000.0 | 2,042,700,000.0 | 454,990,000.0 | — |
Owes vs Owns
Senores Pharmaceuticals Limited owed ₹0.40 for every ₹1 it owned in Mar 2026, down from ₹0.65 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.40× | 0.34× | 0.63× | 0.65× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Senores Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 10.0%Receivables 20.3%Inventory 5.6%Fixed assets (tangible) 22.8%Intangible assets 24.0%Other assets 17.0%
How it's funded — Mar 2026
Short-term debt 8.2%Long-term debt 12.2%Payables 14.6%Other liabilities 4.8%Shareholders' equity 60.1%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 159.6 | 385.5 | 12.9 | 0.1 |
| Receivables | 324.8 | 123.9 | 112.0 | 22.1 |
| Inventory | 89.3 | 56.6 | 37.4 | 3.1 |
| Fixed assets (tangible) | 366.0 | 259.8 | 182.1 | 16.2 |
| Intangible assets | 385.3 | 220.8 | 153.4 | 46.4 |
| Long-term investments | 6.2 | 1.3 | 0.0 | 16.5 |
| Other assets | 272.6 | 179.0 | 124.1 | 26.6 |
| Liabilities & equity | ||||
| Short-term debt | 132.2 | 142.3 | 114.7 | 31.0 |
| Long-term debt | 194.9 | 162.5 | 133.7 | 29.7 |
| Payables | 234.7 | 67.2 | 113.0 | 13.6 |
| Other liabilities | 77.5 | 42.6 | 28.8 | 11.2 |
| Shareholders' equity | 964.5 | 812.2 | 231.7 | 45.5 |
| Net tangible assets | 548.3 | 565.4 | 50.9 | -0.9 |
Senores Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 620,500,000.0 | -459,200,000.0 | -257,000,000.0 | -10,790,000.0 | — |
| Investing Activities | -1,205,600,000.0 | -4,294,800,000.0 | -542,300,000.0 | -482,870,000.0 | — |
| Financing Activities | -13,300,000.0 | 5,731,300,000.0 | 869,800,000.0 | 462,510,000.0 | — |